Skip to content

FOXO4-DRI: The Science and Hype of Senolytic Peptides

August 24, 2026 · 26 min

Show notes

FOXO4-DRI is an experimental peptide categorized as a senolytic, designed to combat aging by selectively eliminating senescent or "zombie" cells that no longer divide. These damaged cells accumulate over time and release inflammatory molecules that contribute to chronic disease and tissue dysfunction. While landmark animal studies showed dramatic results, such as improved kidney function and physical fitness in mice, there are currently no published human clinical trials to confirm its safety or efficacy. Because it lacks formal testing, major questions remain regarding long-term side effects, optimal dosing, and the potential risks of removing cells that might assist in wound healing. Despite these uncertainties, the biohacking community remains highly interested in the compound's potential to treat frailty and age-related decline. Ultimately, the sources emphasize that while the peptide is a significant breakthrough in longevity research, it is not yet a proven medical treatment for humans.

All episodes of Today’s discussion

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.